Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease

2024-9-1

Spare the pain for your gut Treg cells!

2024-9-1

Subscription and Copyright Information

2024-9-1

Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments

2024-9-1

Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy

2024-9-1

Advisory Board and Contents

2024-9-1

Subscription and Copyright Information

2024-8-1

Targeting the STAT3 pathway with STAT3 degraders

2024-8-1

Multiple hERG channel blocking pathways: implications for macromolecules

2024-8-1

Epitope landscape in autoimmune neurological disease and beyond

2024-8-1

Nanotherapy for human papillomavirus-associated cancers: breakthroughs and challenges

2024-8-1

Advisory Board and Contents

2024-8-1

Advances in GPCR-targeted drug development in dermatology

2024-8-1

Role of hypoxia-inducible factor 1 in type 1 diabetes

2024-8-1

Frontiers in CAR-T cell therapy for autoimmune diseases

2024-8-1

Innovating cancer drug discovery with refined phenotypic screens

2024-8-1

Emerging chemophysiological diversity of gut microbiota metabolites

2024-8-1

Magnesium for disease treatment and prevention: emerging mechanisms and opportunities

2024-7-1

Peptide libraries: from epitope mapping to in-depth high-throughput analysis

2024-7-1

Parvalbumin interneuron cell-to-network plasticity: mechanisms and therapeutic avenues

2024-7-1

Subscription and Copyright Information

2024-7-1

PANoptosis: a novel target for cardiovascular diseases

2024-7-1

Targeting epigenetic enzymes for autism treatment

2024-7-1

Targeting TRPM channels for cerebral ischemia–reperfusion injury

2024-7-1

Targeting white adipose tissue to combat insulin resistance

2024-7-1

Targeting extranuclear histones to alleviate acute and chronic inflammation

2024-7-1

Multi-target drugs for Alzheimer's disease

2024-7-1

Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment

2024-7-1

'Living drugs' target CD70 in advanced renal tumors

2024-7-1

Artificial protein coronas: directing nanoparticles to targets

2024-7-1

Potential for targeting small heat shock protein modifications

2024-7-1

Advisory Board and Contents

2024-7-1

BTK inhibitors: past, present, and future

2024-7-1

GPCR-dependent and -independent arrestin signaling

2024-6-20

A novel function of the M2 muscarinic receptor

2024-6-1

Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges

2024-6-1

Malolactone strikes: K-Ras-G12D's Achilles' heel

2024-6-1

Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities

2024-6-1

Subscription and Copyright Information

2024-6-1

Advisory Board and Contents

2024-6-1

Directions to overcome therapy resistance in cancer

2024-6-1

Defeating MYC with drug combinations or dual-targeting drugs

2024-6-1

Tackling therapy resistance in cancer

2024-6-1

Structures reveal how SGLT inhibitors work

2024-6-1

Emerging targets in lipid metabolism for cancer therapy

2024-6-1

Eflornithine for treatment of high-risk neuroblastoma

2024-6-1

Anticancer drugs: How to select small molecule combinations?

2024-6-1

Emerging paradigms and recent progress in targeting ErbB in cancers

2024-5-25

TNIK’s emerging role in cancer, metabolism, and age-related diseases

2024-5-21

Enhancing oncogenic signaling to kill cancer cells

2024-5-10